VITROLAB - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 3,226,825 | 3,007,338 | 3,029,118 | 4,097,759 | 3,760,864 | 3,715,968 | 3,662,398 | 3,348,904 |
| Profit before tax | 915,446 | 500,055 | 670,494 | 1,111,295 | 1,040,998 | 1,073,877 | 1,156,709 | 1,130,798 |
| Net profit | 777,086 | 426,196 | 569,443 | 943,269 | 884,035 | 919,029 | 982,038 | 948,644 |
| Equity | 5,389,077 | 4,815,273 | 5,084,716 | 5,577,985 | 5,862,020 | 6,381,049 | 6,963,087 | 7,511,730 |
| Liabilities | 263,543 | 263,246 | 572,386 | 458,116 | 278,627 | 380,306 | 497,142 | 438,506 |
| Non-current assets | 607,277 | 391,848 | 304,299 | 207,501 | 5,027,777 | 2,220,685 | 5,328,428 | 6,222,543 |
| Current assets | 5,061,307 | 4,709,250 | 5,388,055 | 5,853,305 | 1,155,928 | 4,530,134 | 2,125,374 | 1,722,087 |
| Total assets | 5,668,584 | 5,101,098 | 5,692,354 | 6,060,806 | 6,183,705 | 6,750,819 | 7,453,802 | 7,944,630 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 551,389 | 517,739 | 518,576 |
| Social insurance contributions | - | - | - | - | - | 75,280 | 81,539 | 87,440 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +1.3% | -6.8% | +0.7% | +35.3% | -8.2% | -1.2% | -1.4% | -8.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 13.7% | 8.4% | 10.0% | 15.6% | 14.3% | 13.6% | 13.2% | 11.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 14.4% | 8.9% | 11.2% | 16.9% | 15.1% | 14.4% | 14.1% | 12.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 24.1% | 14.2% | 18.8% | 23.0% | 23.5% | 24.7% | 26.8% | 28.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 28.4% | 16.6% | 22.1% | 27.1% | 27.7% | 28.9% | 31.6% | 33.8% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 302,514 | 279,752 | 297,945 | 406,391 | 421,778 | 464,496 | 462,617 | 375,577 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
VITROLAB - Social security debts
The company had no debts to Sodra
VITROLAB - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-08-19 | 2025-08-19 | 39.18 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
VITROLAB, UAB (code 235279070) is a private limited liability company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €3.35M and net profit of €948.6K, with a profit margin of 28.3%. Revenue decreased from €3.72M in 2023 to €3.66M in 2024 and then to €3.35M in 2025, while net profit remained relatively stable at €919.0K, €982.0K and €948.6K over the same period. This shows a moderate top-line decline alongside resilient profitability. The balance sheet strengthened further in 2025, with total assets increasing to €7.94M and equity to €7.51M, while liabilities stayed low at €438.5K. The equity ratio was 94.5% and debt-to-equity was 0.06, indicating a very conservative capital structure. Return on equity reached 12.6% and return on assets 11.9%, while asset turnover was 0.42x. Revenue per employee was €418.6K and profit per employee was €118.6K.